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Abstract
Introduction: Colorectal cancer (CRC) is the third most com-
mon cancer worldwide, accounting for 10% of the global 
cancer burden. Rectal cancer accounts for around 30% of 
CRC cases, and patients with resectable rectal cancer are of-
ten given preoperative radiotherapy (PRT) to reduce the rate 
of local recurrence. The human plasma proteome is an ex-
ceptionally complex proteome and ideal to study due to its 
ability to reflect the presence of diseases such as cancer and 
the ease of obtaining blood samples. Previous proteomic 
studies involving rectal cancer patients have mostly focused 
on the identification of proteins involved in resistance to ra-
diotherapy. Objective: The aim of this study was to investi-
gate the overall effects of PRT on plasma protein expression 
in rectal cancer patients, as there is a lack of such studies. 
Methods: Here, we have used mass spectrometry and sub-
sequent statistical analyses to analyze the plasma samples of 
30 rectal cancer patients according to PRT status (positive or 
negative) and tumor stage (II or III). Results and Conclusions: 
We discovered 42 proteins whose levels differed significant-
ly between stage II and III rectal cancer patients who did or 
did not receive PRT. This study shows that PRT, although lo-
calized to the pelvis, leads to measurable, tumor stage-spe-
cific changes in plasma protein expression. Future studies of 
plasma proteins should, when relevant, take this into ac-
count and be aware of the widespread effects that PRT has 
on the plasma proteome. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
In 2018, an estimated more than 1.8 million new cases 
of colorectal cancer (CRC) were diagnosed, and almost 
900,000 deaths occurred. These statistics make CRC the 
third most common cancer worldwide and the second 
most common cause of cancer death, second to only lung 
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cancer. CRC therefore accounts for around 10% of the 
global cancer burden [1]. The term CRC encompasses 
cancer in both the colon and rectum, although rectal can-
cer differs from colon cancer in several ways. The rectum 
is located in the pelvis, a narrower space than the abdo-
men, which makes surgical resection more challenging 
for rectal cancer patients and increases the chance of local 
recurrence. Patients with rectal cancer are therefore often 
given neoadjuvant (preoperative) radiotherapy or chemo-
radiotherapy, whereas patients with colon cancer proceed 
directly to surgery. Rectal cancer accounts for approxi-
mately 30% of all CRC cases [2, 3].
Local recurrence is a serious problem for patients with 
rectal cancer as it causes debilitating symptoms and is 
hard to treat, and the incidence of local recurrence can be 
quite high. Preoperative radiotherapy (PRT) has been 
shown to reduce the rate of local recurrence in patients 
with resectable rectal cancer. It is usually given in doses 
of 5 Gy per day over 5 days (short-term PRT), followed 
by surgery [4]. As found by the Swedish Rectal Cancer 
Trial, PRT also improves survival for rectal cancer pa-
tients, which is explained by the reduced risk of local re-
currence. The combination of PRT and surgery has been 
shown to significantly improve both overall and cancer-
specific survival for rectal cancer patients as opposed to 
surgery alone [5, 6].
The proteome is defined as all the proteins expressed 
in a cell, tissue, or organism. Proteomic techniques are 
used to analyze various characteristics of proteins, such 
as their identity, abundance, and function. The proteome 
is complex, due to the multitude of available posttransla-
tional modifications that proteins can undergo, and dy-
namic, as protein expression changes during processes 
such as development and disease [7]. The human plasma 
proteome is exceptionally complex, as it contains other 
tissue proteomes as subsets. The ease of obtaining blood 
samples coupled with the aforementioned complexity 
and dynamic nature of the proteome makes the plasma 
proteome ideal to study. It can reflect the presence of dis-
eases such as cancer, which can for example lead to aber-
rantly secreted proteins that can be detected in the plasma 
[8, 9].
Previous mass spectrometric proteomic studies that 
have analyzed the proteome of cancer patients receiving 
radiotherapy have to a large extent focused on attempts 
to identify proteins that could be used as biomarkers to 
guide the use of radiotherapy by predicting patient re-
sponse [10, 11]. Several studies involving the proteomic 
profiling of rectal cancer patients have also identified pro-
teins implicated in resistance to radiotherapy, such as 
acid ceramidase, or protein signatures predictive of ra-
diotherapy response [12–16]. However, there is a paucity 
of studies with focus on investigating the overall effects of 
radiotherapy on plasma protein expression in rectal can-
cer patients.
The aim of this study was to analyze how widespread 
the effects of PRT are on plasma protein expression in 
rectal cancer patients. Seeing as CRC is the third most 
common cancer worldwide, with its prevalence only pre-
dicted to increase, further studies are needed in order to 
better understand different aspects of this heterogeneous 
disease [17]. The patients were divided into groups based 
on PRT status (positive or negative), as well as tumor 
stage (II or III) in order to more accurately analyze plas-
ma protein expression in a stage-dependent manner. In 
this study, we have analyzed the effects that PRT has on 
the plasma proteome of rectal cancer patients, and dis-
covered significant differences in plasma protein profiles 
depending on PRT status.
Material and Methods
Patient Samples
This study used plasma samples preoperatively (post-radio-
therapy but pre-surgery) obtained from 30 rectal patients (after 
the exclusion of one sample, marked in online supplementary 
Table S1 [see www.karger.com/doi/10.1159/000505697], that 
was not properly digested). The patients in the PRT-positive 
group received preoperative short-course radiotherapy with a 
total dose of 25 Gy administered over 5 days (5 × 5 Gy), after 
which they proceeded immediately to surgery. Plasma samples 
were collected on the day of the operation from all patients, in-
cluding those that did not receive PRT. The patients underwent 
surgical resection at the Department of Surgery, Helsinki Uni-
versity Hospital, between 2000 and 2005. Samples were stored at 
−80°C until processed. Patients with HNPCC, FAP, ulcerative 
colitis, Crohn’s disease, or mucinous tumors were deliberately 
excluded from this study. Detailed patient characteristics can be 
found in Table S1.
The patients were divided into groups according to tumor stage 
(II or III) and PRT status. The preoperative staging by MRI of pa-
tients with stage II tumors who had received PRT was checked in 
order to see if downstaging had been observed in any of these cas-
es. Of these seven patients, one patient had stage III disease at the 
time of diagnosis (N1), one patient had not undergone a preop-
erative MRI (NX), and the remaining five patients were negative 
for regional lymph node metastases (N0). Therefore, in the major-
ity of cases, the preoperative stage correlated with the pathological 
stage that was determined postoperatively. The clinical data was 
obtained from patient records, the survival data from the Popula-
tion Register Center of Finland, and the cause of death for all the 
deceased from Statistics Finland. This study was a retrospective 
study that used plasma samples prospectively collected between 
2000 and 2005. Participants provided written informed consent 
regarding plasma sample collection for future studies. This study 
Preoperative Radiotherapy Affects Plasma 
Protein Expression
495Oncology 2020;98:493–500
DOI: 10.1159/000505697
was planned as a small pilot study and the samples analyzed here 
may not be representative of a larger population. This study was 
approved by the Surgical Ethics Committee of Helsinki University 
Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 April 17, 
2013) and was conducted according to the principles expressed in 
the Declaration of Helsinki.
Before the start of the study, we had assumed mean 1 to be 100, 
mean 2 to be 200, and the fold change to be 2. The common stan-
dard deviation was assumed to be 75% of mean 1. This gave us a 
sample size of 7 per group to differentiate the groups. However, 
the standard deviation common to both the groups was found to 
be larger after the study was carried out. Post-study, we have cal-
culated the appropriate sample size for achieving 80% power for 
our top changing proteins to differentiate the two groups. For the 
stage II comparison, it was found to be 12 samples per group (me-
dian) and for the stage III comparison, it was 11 samples (medi-
an). When we calculated the power for our sample size, it was 
found to be in the range of 35–71% for stage II samples and 65–
84% for stage III samples, which is an acceptable power for a pilot 
study.
Sample Processing
The plasma samples were processed as previously described 
[18]. To summarize, the plasma samples were thawed and top 12 
protein depletion was performed. The protein concentration in 
each sample was determined and the amount of plasma equiva-
lent to 100 μg of protein was aliquoted and dried. The dried 
plasma samples were then dissolved in Tris buffer containing 
urea and the samples were further processed and diluted. Tryp-
sin digestion was performed overnight, after which 30 μg of tryp-
tic peptides were cleaned and the cleaned peptides were dis-
solved in formic acid containing Hi3 spike-in standard peptides 
for quantification.
Ultra Performance Liquid Chromatography-Ultra Definition 
Mass Spectrometry and Quantification
UPLC-UDMSE was performed as previously described [18]. 
Data were acquired with a Synapt G2-S HDMS (Waters Corpora-
tion, MA, USA) in data-independent acquisition fashion using 
UDMSE mode. Calibration was performed with sodium iodide 
clusters over a mass range of 50–2,500 m/z by infusing 2 μg/μL so-
dium iodide solution in 50/50 2-propanol/water into the mass 
spectrometer.
Data Analysis
Data analysis and label-free quantification were performed as 
previously described [18, 19]. The raw files were imported to Pro-
genesis QI for proteomics (Nonlinear Dynamics, Newcastle, UK) 
and post-acquisition mass correction was performed when the raw 
data was imported into Progenesis with a lock mass ion of M+H+ 
556.2771 m/z. Leucine enkephalin (C25H37O7, 1 ng/μL in 50:50 
acetonitrile:water +0.1% formic acid) was infused into the refer-
ence sprayer at 300 nL/min for this correction.
Default parameters were used for peak picking and alignment 
and the peptide identification was done against Uniprot human 
FASTA sequences (release 2018_04). A ClpB protein sequence 
(CLPB_ECOLI [P63285]) was inserted for label-free quantifica-
tion. Fixed modification at cysteine (carbamidomethyl) and vari-
able at methionine (oxidation) were used. Trypsin was used as a 
digesting agent, and one missed cleavage was allowed. Fragment 
Table 1. The proteins that passed the cutoff of a Mann-Whitney U test p value of less than 0.05 when samples from patients with stage 
II rectal cancer were analyzed according to preoperative radiotherapy (PRT) status (positive or negative)
Accession Peptide 
count
Unique 
peptides
Confidence 
score
Mann-
Whitney U 
test p value
Fold 
change 
(stage II 
PRT +/–)
Protein name Gene name
P68871; P69891; P69892 15 8 119.2 1.92E–02 –4.1 Hemoglobin subunit beta HBB
P61626 5 4 24.0 3.71E–02 –3.0 Lysozyme C LYZ
P69905 9 6 73.5 3.71E–02 –2.9 Hemoglobin subunit alpha HBA1
Q01432 3 2 14.5 3.71E–02 –2.6 AMP deaminase 3 AMPD3
P42336 13 7 66.7 3.71E–02 –1.8 Phosphatidylinositol 4_5-bisphosphate 
3-kinase catalytic subunit alpha isoform
PIK3CA
B1AJZ9 10 3 49.0 2.69E–02 –1.6 Forkhead-associated domain-containing 
protein 1
FHAD1
Q13976 16 6 70.8 3.71E–02 –1.5 cGMP-dependent protein kinase 1 PRKG1
H7BZ55 9 6 52.9 3.71E–02 –1.4 Putative ciliary rootlet coiled-coil 
protein 2
CROCC2
P08571 7 5 62.2 2.69E–02 –1.3 Monocyte differentiation antigen CD14 CD14
P04217 120 105 643.9 1.34E–02 –1.3 Alpha-1B-glycoprotein A1BG
P23508 5 3 27.9 2.69E–02 –1.3 Colorectal mutant cancer protein MCC
P02790; P51687; Q00973; Q04917; 
Q5T013; Q9NXR7; Q9NZ08; 
Q9Y2H2; Q9Y2K5; V9GYY9
182 150 1,011.0 2.69E–02 –1.3 Hemopexin HPX
Q9NZP8 9 5 72.5 2.69E–02 –1.3 Complement C1r subcomponent-like 
protein
C1RL
P36955 32 21 245.7 3.71E–02 –1.3 Pigment epithelium-derived factor SERPINF1
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and peptide error tolerances were set to automatic settings and the 
false discovery rate was set to less than 2%. For ion matching, one 
or more ion fragments per peptide, three or more fragments per 
protein, and one or more peptides per protein were required (the 
default parameters). The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via the 
PRIDE [20] partner repository with the dataset identifier 
PXD013150 and 10.6019/PXD013150.
Further Analysis
The differences between the groups were analyzed using the 
Mann-Whitney U test or T test. The Mann-Whitney U test was 
used when the abundances of the majority (>50%) of proteins were 
not normally distributed, while the T test was used when the abun-
dances of the majority (>50%) of proteins were normally distrib-
uted. Box plots were drawn using GraphPad Prism 7 (GraphPad 
Software, La Jolla, CA, USA).
Results
In this study, we analyzed the plasma samples from 30 
rectal cancer patients into groups based on whether the 
patients had received PRT or not. This was done in order 
to study if PRT leads to differences in plasma protein ex-
pression between patients. We compared patients ac-
cording to PRT status separately depending on whether 
patients had stage II or III rectal cancer.
Among stage II rectal cancer patients, 7 received PRT 
and 6 patients did not. A total of 14 proteins passed the 
cutoff of a Mann-Whitney U test p value of less than 0.05 
(Table 1) when samples from these patients were com-
pared according to PRT status. All 14 proteins displayed 
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Fig. 1. The normalized abundance of the top three proteins accord-
ing to fold change as box plots when samples from stage II rectal 
cancer patients were compared according to preoperative radio-
therapy status. The box plots were plotted using the Tukey method 
and show the median, quartiles, and outliers. a Normalized abun-
dance of HBB. b Normalized abundance of lysozyme C (LYZ). 
c Normalized abundance of hemoglobin subunit alpha (HBA1).
Fig. 2. The normalized abundance of the 
top two proteins according to fold change 
as box plots when samples from stage III 
rectal cancer patients were compared ac-
cording to preoperative radiotherapy sta-
tus. The box plots were plotted using the 
Tukey method and show the median, quar-
tiles, and outliers. a Normalized abun-
dance of serum amyloid A1 (SAA1). b Nor-
malized abundance of synapsin 2 (SYN2).
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higher levels in the plasma of stage II rectal cancer pa-
tients who were PRT negative. The protein with the larg-
est fold change (4.1) was hemoglobin subunit beta (HBB), 
which displayed higher plasma levels in patients who 
were negative for PRT. Figure 1 shows the normalized 
abundance of the top three proteins in stage II rectal can-
cer patients who were PRT positive or negative as box 
plots.
Among stage III rectal cancer patients, 9 patients re-
ceived PRT and 8 did not. In this group, a total of 28 pro-
teins passed the cutoff of a T test p value of less than 0.05 
(Table 2) when samples from these patients were com-
pared. In contrast to the proteins identified in stage II 
rectal cancer patients, all of these 28 proteins displayed 
higher levels in the plasma of stage III rectal cancer pa-
tients who received PRT. The protein with the largest fold 
change (2.2) was serum amyloid A-1 (SAA1), which had 
higher plasma levels in patients who were positive for 
PRT. Figure 2 shows the normalized abundance of the top 
two proteins in stage III rectal cancer patients who were 
PRT positive or negative as box plots.
Discussion
In this study, we have analyzed the differences in plasma 
protein expression between a small group of rectal cancer 
patients who were divided into groups based on PRT status 
Table 2. The proteins that passed the cutoff of a T test p value of less than 0.05 when samples from patients with stage III rectal cancer 
were analyzed according to PRT status (positive or negative)
Accession Peptide 
count
Unique 
peptides
Confidence 
score
T test 
p value
Fold change 
(stage III 
PRT +/–)
Protein name Gene name
P0DJI8 19 9 130.6 4.44E–02 2.2 Serum amyloid A-1 protein SAA1
Q92777 5 3 27.1 1.84E–02 2.2 Synapsin-2 SYN2
P18428 7 5 39.1 4.25E–02 1.8 Lipopolysaccharide-binding protein LBP
Q6UXB8 3 2 15.0 2.46E–02 1.8 Peptidase inhibitor 16 PI16
Q04756 11 9 62.9 1.54E–02 1.7 Hepatocyte growth factor activator HGFAC
Q3V6T2 15 6 70.1 4.66E–02 1.6 Girdin CCDC88A
P69905 9 6 73.5 2.19E–02 1.6 Hemoglobin subunit alpha HBA1
H7BZ55 9 6 52.9 6.50E–03 1.6 Putative ciliary rootlet coiled-coil 
protein 2
CROCC2
P68871; P69891; P69892 15 8 119.2 3.18E–02 1.5 Hemoglobin subunit beta HBB
P05543 17 11 109.5 2.72E–02 1.5 Thyroxine-binding globulin SERPINA7
Q9P2D0 4 2 23.1 6.92E–03 1.4 Inhibitor of Bruton tyrosine kinase IBTK
P05156; Q5SWL8 63 54 485.7 1.26E–03 1.4 Complement factor I CFI
Q5TB30; Q13884 7 5 33.1 2.71E–02 1.4 DEP domain-containing protein 1A DEPDC1
Q15166 6 2 62.1 4.00E–02 1.4 Serum paraoxonase/lactonase 3 PON3
P02749 94 87 516.2 4.91E–03 1.4 Beta-2-glycoprotein 1 APOH
Q92598 14 9 91.6 2.81E–02 1.3 Heat shock protein 105 kDa HSPH1
P17936 9 2 36.0 3.58E–02 1.3 Insulin-like growth factor-binding 
protein 3
IGFBP3
P13671 48 35 411.8 4.46E–04 1.3 Complement component C6 C6
P08603 117 97 914.4 3.44E–02 1.3 Complement factor H CFH
P02765 93 76 435.3 4.64E–02 1.3 Alpha-2-HS-glycoprotein AHSG
B4E1Z4; P00751 222 167 1,424.3 9.00E–03 1.3 cDNA FLJ55673_ highly similar to 
Complement factor B (EC 3.4.21.47)
P01019 38 33 309.3 4.22E–02 1.3 Angiotensinogen AGT
O75882 16 12 98.9 2.80E–02 1.3 Attractin ATRN
P04004 93 77 458.1 1.18E–02 1.3 Vitronectin VTN
P02760 54 47 372.8 2.35E–02 1.2 Protein AMBP AMBP
O95445 13 12 64.0 2.43E–02 1.2 Apolipoprotein M APOM
P01042 89 82 598.1 2.80E–02 1.2 Kininogen-1 KNG1
P02790; P51687; Q00973; Q04917; 
Q5T013; Q9NXR7; Q9NZ08; 
Q9Y2H2; Q9Y2K5; V9GYY9
182 150 1,011.0 6.05E–03 1.2 Hemopexin HPX
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and tumor stage (II or III). This was done in order to study 
the differences in plasma protein expression in a stage-spe-
cific manner. Here, we discovered 14 plasma proteins 
whose levels differed significantly depending on PRT sta-
tus in stage II rectal cancer patients, and 28 plasma proteins 
whose levels differed significantly between stage III rectal 
cancer patients. Levels of three proteins, HBB, hemoglobin 
subunit alpha (HBA1), and hemopexin (HPX), were sig-
nificantly altered between samples from both stage II and 
III rectal cancer patients. However, in stage II patients, lev-
els of these proteins were higher in patients who were PRT 
negative, while in stage III patients, they were higher in 
patients who were PRT positive. These findings indicate 
that PRT can have different effects on plasma protein ex-
pression depending on tumor stage.
We have previously compared plasma samples from 
CRC patients according to patient survival, where pa-
tients were divided into groups based on whether they 
survived or died due to CRC. Patients who died due to 
stage II CRC were found to have higher plasma levels of 
HBB than patients who survived having stage II CRC (un-
published data; the raw mass spectrometric data can be 
found in the PRIDE [20] repository with the dataset iden-
tifier PXD013150). These findings indicate that higher 
plasma levels of HBB may be linked to poor outcome in 
patients with stage II CRC. PRT has also been found to 
improve survival [6], and we have found that stage II rec-
tal cancer patients who did not receive PRT had higher 
levels of plasma HBB (fold change of 4.1), which further 
supports the conclusion that higher levels of HBB may 
affect patient survival. A study by Zheng et al. [21] showed 
that expression of HBB by circulating tumor cells pro-
motes cell survival during hematogenous dissemination 
in breast, prostate, and lung cancer. Circulating tumor 
cells displayed an elevated expression of HBB, which also 
promoted the initiation of distant metastases in mouse 
models of breast cancer. The authors also found that HBB 
protects epithelial cancer cells from reactive oxygen spe-
cies (ROS)-induced apoptosis [21]. Additional studies are 
needed in order to investigate the role of HBB in CRC and 
if elevated levels of HBB could directly affect factors such 
as cancer aggressiveness and metastasis. HBB could for 
example be studied in a larger series of patients using 
commercially available ELISA kits in order to examine a 
possible link between HBB expression and factors such as 
response to radiotherapy or patient survival.
Radiotherapy causes DNA damage either through the 
ionization of DNA or the generation of ROS, which leads 
to single- and double-strand breaks, as well as other DNA 
lesions [22, 23]. The main cell death mechanisms follow-
ing exposure to irradiation are radiation-induced apop-
tosis and mitotic catastrophe (cell death that occurs dur-
ing or due to aberrant mitosis) [24]. Expression of hemo-
globin subunit epsilon (HBE1, also known as epsilon 
globin), which encodes a subunit of hemoglobin, is nor-
mally silenced in adults. However, HBE1 has been found 
to be overexpressed in CRC cell lines made resistant to 
radiotherapy by exposure to ionizing radiation over sev-
eral weeks. These cells displayed decreased ROS produc-
tion and cell death when subsequently exposed to radia-
tion [25]. Hemoglobin, which is a complex of heme and 
globin, has been discovered to increase proliferation in 
CRC cells through the production of ROS [26]. In this 
study, the plasma levels of both HBA1 and HBB, as well 
as the levels of HPX, were altered between rectal cancer 
patients depending on PRT status. HPX is a plasma pro-
tein that binds heme released from heme-binding pro-
teins such as hemoglobin [27]. These results indicate that 
the generation of ROS caused by radiotherapy directly 
affects heme levels and may also affect different aspects of 
CRC, such as cell proliferation and survival.
There is a lack of proteomic studies investigating how 
PRT affects the plasma proteome and profiling the differ-
ences between rectal cancer patients who did or did not 
receive PRT. In this study, we have shown that the levels 
of multiple plasma proteins differ between rectal cancer 
patients depending on PRT status, with stage-specific dif-
ferences being seen. Fold changes were generally larger for 
the proteins whose levels differed between stage II rectal 
cancer patients, ranging from 1.3 to 4.1 (compared to 
from 1.2 to 2.2 for stage III patients), while the levels of 
more proteins differed significantly between stage III than 
stage II rectal cancer patients (28 vs. 14). Our results show 
that PRT, although localized to the pelvis for rectal cancer 
patients, leads to significant changes in plasma protein ex-
pression that can be detected and quantified from easily 
obtainable blood samples. Seeing as PRT significantly af-
fects plasma protein expression, PRT status has to be tak-
en into consideration when studying the plasma pro-
teome. It is important to be aware of the fact that PRT 
leads to changes in the levels of specific plasma proteins, 
especially if these proteins are the subjects of future stud-
ies in situations where patients may have received PRT.
Although this study analyzed the plasma samples of a 
relatively small cohort of 30 rectal cancer patients, we 
have identified multiple plasma proteins whose levels dif-
fer according to PRT status in patients with stage II or III 
rectal cancer. Whereas previous studies have to a large 
extent focused on identifying proteins that can function 
as biomarkers of response to radiotherapy and proteins 
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involved in resistance to radiotherapy, this study has in-
vestigated the overall differences in plasma protein ex-
pression depending on whether patients did or did not 
receive PRT. This study shows that PRT leads to wide-
spread, significant changes in plasma protein expression. 
This is something that accordingly must be taken into ac-
count in future studies involving plasma proteins where 
patients may have received PRT. These results suggest 
that PRT may also significantly affect the plasma protein 
profiles of patients with other types of cancer treated with 
PRT, such as breast, prostate, and cervical cancer.
Further studies are needed to investigate if PRT status 
also needs to be taken into account in relevant studies of 
these types of cancer. The findings of this study support 
the further analysis of proteins discovered here, such as 
HBB, in a larger series of samples using ELISA assays to 
study the link between protein expression and factors 
such as PRT response and patient survival. Additionally, 
future studies should aim to analyze the plasma protein 
expression in a larger set of samples collected before and 
after PRT from the same patients, which was unfortu-
nately not possible here, as no plasma samples were col-
lected prior to PRT. However, this pilot study has shown 
that PRT significantly affects plasma protein expression 
and is something that should be further investigated.
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